Article

Combination therapy effective for patients receiving multiple and monotherapy glaucoma regimens

A combination anti-glaucoma drug that includes brimonidine tartrate ophthalmic solution 0.2% and timolol ophthalmic solution 0.5% (Combigan, Allergan) has a significant impact on the IOP of most patients regardless of gender and whether they are undergoing multiple or monotherapy for glaucoma, said Saad Younis, MD, from West Middlesex University and Ashford Hospital, Middlesex, United Kingdom.

A combination anti-glaucoma drug that includes brimonidine tartrate ophthalmic solution 0.2% and timolol ophthalmic solution 0.5% (Combigan, Allergan) has a significant impact on the IOP of most patients regardless of gender and whether they are undergoing multiple or monotherapy for glaucoma, said Saad Younis, MD, from West Middlesex University and Ashford Hospital, Middlesex, United Kingdom.

"Patients requiring multiple ocular antihypertensive drugs to control IOP may benefit from fixed combinations that offer reduced exposure to the potentially toxic effects of the preservative benzalkonium chloride, removal of the risk of washout of the first instilled medication, and improved chances of patient compliance with the prescribed regimen," Dr. Younis explained.

Dr. Younis conducted this study to investigate the ocular hypotensive effect of the combination anti-glaucoma drug and evaluate the medication's effect on men and women. Glaucoma patients receiving treatment and exhibiting visual field or progressive IOP damage were included. Patients who needed a change in medication because of adverse events were excluded.

Nineteen women and 18 men were included (mean age of women, 68.5; mean age of men, 66.5 years). Twenty patients had been treated with monotherapy before they received the combination anti-glaucoma drug; 17 patients had been on multiple therapy regimens. The mean baseline IOP was 24.2 and 25.6 mm Hg in women and men, respectively. Eight patients left the study (five because of an allergic reaction to the combination anti-glaucoma drug and three because of insufficient IOP control). No systemic side effects developed.

Dr. Younis reported that the mean IOP reductions in all women were 4.13 ± 3.71 mm Hg and 5.23 ± 3.39 mm Hg, when patient withdrawals were excluded from analysis. The mean IOP decreases in all men were 4.06 ± 3.9 mm Hg and 5.21 ± 3.66 mm Hg when patient withdrawals were excluded. Overall the mean IOP reduction after the addition of the combination anti-glaucoma drug in all patients was 4.09 ± 3.75 mm Hg. When patient withdrawals were excluded the mean IOP in all patients was 5.22 ± 3.46 mm Hg.

"This study indicated that [the combination anti-glaucoma drug] has a clinically significant impact on the IOP of most patients whether male or female and whether they are on multiple or monotherapy for glaucoma," Dr. Younis said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.